Compare Definium Therapeutics Inc. Common Shares (DFTX) vs Lemonade Inc (LMND) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Definium Therapeutics Inc. Common Shares vs Lemonade Inc — how do they compare? Definium Therapeutics Inc. Common Shares trades at $35.59 (market cap $4.59B), while Lemonade Inc trades at $47.34 (market cap $3.63B). The key difference: Definium Therapeutics Inc. Common Shares is the larger of the two by market cap, and Definium Therapeutics Inc. Common Shares is trading nearer its 52-week high, Lemonade Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Definium Therapeutics Inc. Common Shares for 0 Days and Lemonade Inc for 27 Days on average.
| DFTX | LMND | |
|---|---|---|
Market Cap | $4.59B | $3.63B |
Volume | 2,103,937 | 1,544,794 |
Sector | Health | Financials |
52-Week High | $48.45 | $96.57 |
52-Week Low | $10.68 | $43.91 |
Typical Hold Time | 0 Days | 27 Days |
Enterprise Value | $3.55B | $3.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Lemonade (LMND) trades at $46.83, up 1.14% with a bearish technical outlook despite recent earnings beats. The company shows strong revenue growth from $257M in 2022 to $738M in 2025, though remains unprofitable with a -22.43% net margin. Analyst sentiment is evenly split between buy/hold/sell with a $67 consensus target, while institutional activity shows mixed positioning. Recent expansion into Alaska and Kentucky renters insurance and pet insurance markets supports growth trajectory.
Lemonade's path to profitability remains the key investment thesis, targeting EBITDA positivity by late 2026. The stock offers growth potential through AI-driven efficiency and market expansion but carries significant execution risk amid persistent losses. Current valuation at 3.63x sales appears reasonable for the growth profile, though technical weakness near support at $45 requires monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Definium Therapeutics Inc. Common Shares
Definium Therapeutics develops investigational treatments for psychiatric and neurological disorders. Formerly MindMed, it focuses on clinical-stage therapies based on novel psychoactive compounds.
Read more on DFTX →About Lemonade Inc
Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes.
Read more on LMND →
